ING Groep NV Makes New Investment in Boston Scientific Corporation $BSX

ING Groep NV purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 247,296 shares of the medical equipment provider’s stock, valued at approximately $24,144,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter valued at $26,000. Steph & Co. purchased a new position in Boston Scientific in the third quarter worth about $25,000. Financial Consulate Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $25,000. United Community Bank increased its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at about $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BSX shares. Barclays dropped their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Evercore dropped their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Canaccord Genuity Group reduced their price objective on Boston Scientific from $131.00 to $112.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Oppenheimer decreased their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Finally, BTIG Research reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.43.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Up 0.2%

Shares of BSX stock opened at $74.26 on Wednesday. Boston Scientific Corporation has a 52-week low of $73.92 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a market capitalization of $110.09 billion, a PE ratio of 38.28, a PEG ratio of 1.55 and a beta of 0.67. The stock has a fifty day simple moving average of $92.36 and a two-hundred day simple moving average of $98.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business’s revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.